HIMS (Hims & Hers Health, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by HIMS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-27 | Andrew Dudum | Chief Executive Officer | MIXED | — | — |
| 2026-08-20 | Oluyemi Okupe | Chief Financial Officer | MIXED | — | — |
| 2026-08-20 | Deborah M. Autor | Chief Policy Officer | Sell | — | — |
| 2026-08-20 | Soleil Boughton | Chief Legal Officer | Sell | — | — |
| 2026-08-18 | Kare Schultz | Director | M | — | — |
| 2026-08-18 | Christopher D Payne | Director | M | — | — |
| 2026-08-18 | Mohamed Elshenawy | CTO | MIXED | — | — |
| 2026-08-18 | DAVID B WELLS | Director | M | — | — |
| 2026-08-18 | Patrick Harrison Carroll | Chief Medical Officer | MIXED | — | — |
| 2026-08-18 | Soleil Boughton | Chief Legal Officer | MIXED | — | — |
| 2026-08-18 | Irene Becklund | PAO | MIXED | — | — |
| 2026-08-18 | Oluyemi Okupe | Chief Financial Officer | MIXED | — | — |
| 2026-08-18 | Andrew Dudum | Chief Executive Officer | MIXED | — | — |
| 2026-08-18 | Michael Chi | Chief Operating Officer | MIXED | — | — |
| 2026-08-18 | Deborah M. Autor | Chief Policy Officer | MIXED | — | — |
| 2026-08-14 | Delos M. Cosgrove | Director | A | — | — |
| 2026-08-14 | Patrick Harrison Carroll | Chief Medical Officer | A | — | — |
| 2026-08-14 | Anja Manuel | Director | A | — | — |
| 2026-08-14 | DAVID B WELLS | Director | A | — | — |
| 2026-08-14 | Deborah M. Autor | Chief Policy Officer | A | — | — |
| 2026-08-14 | Christopher D Payne | Director | A | — | — |
| 2026-08-14 | Garcia Andrea G Perez | Director | A | — | — |
| 2026-08-14 | Kare Schultz | Director | A | — | — |
| 2026-08-14 | Kofi Owusu Amoo-Gottfried | Director | A | — | — |
| 2026-08-14 | Mohamed Elshenawy | CTO | A | — | — |
| 2026-07-20 | Oluyemi Okupe | Chief Financial Officer | MIXED | — | — |
| 2026-07-07 | Oluyemi Okupe | Chief Financial Officer | MIXED | — | — |
| 2026-06-23 | Patrick Harrison Carroll | Chief Medical Officer | Sell | — | — |
| 2026-06-23 | Oluyemi Okupe | Chief Financial Officer | MIXED | — | — |
| 2026-06-17 | Deborah M. Autor | Chief Policy Officer | MIXED | — | — |
| 2026-06-17 | Mohamed Elshenawy | CTO | MIXED | — | — |
| 2026-06-17 | Soleil Boughton | Chief Legal Officer | MIXED | — | — |
| 2026-06-17 | Patrick Harrison Carroll | Chief Medical Officer | MIXED | — | — |
| 2026-06-17 | Oluyemi Okupe | Chief Financial Officer | MIXED | — | — |
| 2026-06-17 | Michael Chi | Chief Operating Officer | MIXED | — | — |
| 2026-06-17 | Andrew Dudum | Chief Executive Officer | MIXED | — | — |
| 2026-06-17 | Irene Becklund | PAO | MIXED | — | — |
| 2026-06-15 | Kare Schultz | Director | M | — | — |
| 2026-06-15 | Christopher D Payne | Director | M | — | — |
| 2026-06-15 | Delos M. Cosgrove | Director | M | — | — |
| 2026-06-15 | Christiane Pendarvis | Director | M | — | — |
| 2026-06-15 | Deborah M. Autor | Chief Policy Officer | M | — | — |
| 2026-06-15 | Anja Manuel | Director | M | — | — |
| 2026-06-15 | Garcia Andrea G Perez | Director | M | — | — |
| 2026-06-15 | Patrick Harrison Carroll | Chief Medical Officer | M | — | — |
| 2026-06-15 | DAVID B WELLS | Director | M | — | — |
| 2026-05-26 | DAVID B WELLS | Director | Buy | — | — |
| 2026-05-22 | DAVID B WELLS | Director | A | — | — |
| 2026-05-22 | Christopher D Payne | Director | A | — | — |
| 2026-05-22 | Patrick Harrison Carroll | Chief Medical Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 8,973,272 | — |
| — | Director | 7,753,813 | — |
| — | 10%+ Owner | 6,239,205 | — |
| — | Chief Executive Officer | 1,606,379 | — |
| — | Chief Operating Officer | 824,630 | — |
| — | Chief Operating Officer | 470,687 | — |
| — | Chief Legal Officer | 313,964 | — |
| — | CTO | 289,308 | — |
| — | Chief Financial Officer | 271,970 | — |
| — | Director | 229,808 | — |
| — | Chief Medical Officer | 208,048 | — |
| — | Director | 177,581 | — |
| — | Director | 148,621 | — |
| — | Director | 144,863 | — |
| — | Director | 90,985 | — |
| — | Director | 83,822 | — |
| — | Director | 67,995 | — |
| — | 10%+ Owner | 62,500 | — |
| — | Chief Financial Officer | 61,935 | — |
| — | 10%+ Owner | 61,320 | — |
| — | Director | 55,430 | — |
| — | Chief Policy Officer | 48,961 | — |
| — | Director | 28,631 | — |
| — | Director | 26,020 | — |
| — | PAO | 13,985 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HIMS quote page; the site-wide leaderboard is on the insider transactions hub.